Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.
Thomas M. Habermann, MD
Advertisement
Articles by Thomas M. Habermann, MD
Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.
Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.
Thomas M. Habermann, MD, discusses the evolving treatment landscape of mantle cell lymphoma.
Advertisement
Latest Updated Articles
Dr Habermann on Data Leading to the Withdrawal of Ibrutinib in MCLPublished: May 16th 2023 | Updated:
- Dr Habermann on the Withdrawal of U.S. Indications for Ibrutinib in MCL and MZL
Published: May 12th 2023 | Updated:
Dr Habermann on the Evolving Treatment Landscape of Mantle Cell LymphomaPublished: May 8th 2023 | Updated:
- Dr Habermann on Ongoing Trials in MCL and MZL
Published: May 16th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5